(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 June 2011 (09.06.2011)

PCT

(10) International Publication Number
WO 2011/068667 A1

(51) International Patent Classification:
A61K 31/50 (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/US2010/056712

(22) International Filing Date:
15 November 2010 (15.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/266,801 4 December 2009 (04.12.2009) US
61/354,165 11 June 2010 (11.06.2010) US

(71) Applicant *(for all designated States except US)*: **CYLENE PHARMACEUTICALS, INC.** [US/US]; 5820 Nancy Ridge Drive, Suite 200, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HADDACH, Mustapha** [US/US]; 14744 Via Mantova, San Diego, California 92127 (US). **TRAN, Joe, A.** [US/US]; 1498 Clearview Way, San Marcos, California 92078 (US). **PIERRE, Fabrice** [FR/US]; 3244 Caminito Eastbluff, #40, La Jolla, California 92037 (US). **REGAN, Collin, F.** [US/US]; 981 North Vulcan, Unit 2, Encinitas, California 92024 (US). **RAFFAELE, Nicholas, B.** [US/US]; 2606 Illion Street, San Diego, California 92110 (US). **RAVULA, Suchitra** [IN/US]; 17019 New Rochelle Way, San Diego, California 92127 (US). **RYCKMAN, David, M.** [US/US]; 5675 Willowmere Lane, San Diego, California 92130 (US).

(74) Agents: **WU, Nan** et al.; Cooley LLP, 777 6th Street, NW, Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS



(I)

(57) Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula (I)..

WO 2011/068667 A1